Products for Research Use Only
RegisterLogin

EX229

CAT: 0804-HY-112769-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112769-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
EX229, a Benzimidazole derivative, is a potent and allosteric activator of AMP-activated protein kinase (AMPK), with Kds of 0.06 μM, 0.06 μM and 0.51 μM for α1β1γ1, α2β1γ1 and α1β2γ1 in biolayer interferometry, respectively.
CAS Number
1219739-36-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
AMPK
Type
Reference compound
Related Pathways
Epigenetics; PI3K/Akt/mTOR
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/EX229.html
Purity
99.44
Solubility
DMSO : 13 mg/mL (ultrasonic; warming)
Smiles
O=C(O)C1=CC(OC2=NC3=CC(Cl)=C(C4=CC5=C(N(C)C=C5)C=C4)C=C3N2)=CC=C1C
Molecular Formula
C24H18ClN3O3
Molecular Weight
431.87
Precautions
H302, H315, H319, H335
References & Citations
[1]Xiao B, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017.|[2]Bultot L, et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. Am J Physiol Endocrinol Metab. 2016 Oct 1;311 (4) :E706-E719.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
AMPK α1β1γ1; AMPK α1β2γ1; AMPK α2β1γ1

Alternative Products

CatalogName
BA4623-50EX229
C13565-25mgEx229 (compound 991)
A16795-100Ex229 (compound 991) 100mg
A16795-5Ex229 (compound 991) 5mg
A16795-2Ex229 (compound 991) 2mg
A16795-1Ex229 (compound 991) 1mg
441491-01AMPK Activator 991 (EX229)
A16795-50Ex229 (compound 991) 50mg
A16795-25Ex229 (compound 991) 25mg
A16795-10Ex229 (compound 991) 10mg

Popular Products